MyFinsight
Home
Blog
About
Contact
Download
Download image
Investment in preferred
stock qcls
$22,472,000
Warrant asset qcls non
current
$10,242,000
Intangible asset
$1,549,427
Warrant asset femasys
$906,000
Other assets
$7,688
Cash and cash
equivalents
$20,165,535
Marketable equity
securities
$372,251
Prepaid expenses and
other current assets
$158,664
Total other assets
$35,177,115
Total current assets
$20,696,450
Total assets
$55,873,565
Total liabilities,
temporary equity and...
$55,873,565
Total stockholders
equity
$38,113,013
Total liabilities
$16,471,229
Total temporary
equity
$1,289,323
Accumulated deficit
-$100,000,171
Treasury stock, at cost,
15,270,066 and 14,876,316...
$45,009,541
Accumulated other
comprehensive loss
-$21,540
Additional paid-in capital
$183,141,663
Total other
liabilities
$14,793,000
Total current
liabilities
$1,678,229
Convertible preferred
stock-Series CPreferred...
$872,323
Contingently redeemable
warrants
$417,000
Common stock
authorized 200,000,000...
$2,602
Warrant liabilities
$13,657,000
Derivative liabilities
$1,136,000
Accounts payable
$1,200,082
Accrued expenses
$445,656
Accrued series c
dividends
$32,491
Back
Back
Balance Sheet
source: myfinsight.com
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)